IL18 and systemic lupus erythematosus: A cohort study of 96 pediatric SLE patients demonstrated that elevated serum IL-18 levels at 6 months post-treatment were linked to adverse clinical outcomes, though there were no findings related to urinary IL-18 or renal pathology (Wu et al., 2016).